The authors evaluated the isoniazid acetylating phenotype and measured hematocrit, he moglobin, glucose-6-phosphate dehydrogenase and glutathione reductase activities plu s serum sulfadoxin levels in 39 patients with paracoccidioidom ycosis (33 m ales and 6 fem ales) aged 17 to 58 years. Twenty one (5 3 .8 4 % ) o f the patients presented a slow acetylatingphenotype and 18(46.16% ) a fa s t acetylating phenotype. Glucose-6-phosphate-dehydrogenase ( G 6PD) acti vity was decreased in 5(23.80% ) slow acetylators and in 4(22.22% ) fa st acetylators. Glutathione reductase activity was decreased in 14(66.66% ) slow acetylators and in 12(66.66% )fa s t acetylators. Serum levels o f free and total sulfadoxin Were higher in slow acetylator(p < 0.02). A nalysis o f the results<permitted us to conclude that serum sulfadoxin levels are related to the acetylatorphenotype. Furthermore, sulfadoxin levels were always above 50 jig/ml, a value considered therapeutic. Glutathione reductase deficiency observed in 66% of patients may be related to the intestinal malabsorption of nutrients, among them riboflavin, a FAD precursor vitamin, inpatients withparacoceidioidomycosis.
The therapeutic conduct adopted by us thus far® 18 for paracoccidioidomycosis is divided into two stages, i.e. acute and maintenance treatment Several drugs have been employed for acute treatment, among them sulfa drugs alone17 or in combination with trimethoprim^ 7 18. For maintenance, the use of slowexcretion sulfa drugs is recommended for a period of at least two years 18. These drugs, because of their oxidizing action, may cause serious side effects in patients with genetic red blood cell defects1 3 4 6 9 14 21 . Among such defects are glucose-6-phosphate dehydrogenase (G6PD) and glutathione reductase deficiency3 14. Glutathione reductase deficiency also may be an acquired defect due to deficiency of riboflavin, a FAD precursor vitamin^ 14 These defects may cause attacks of hemolytic anemia in patients treated for paracoccidioidomycosis, with con sequent severe worsening of clinical signs and progno sis.
In addition, the literature is controversial with respect to the effect of isoniazid acetylating phenotype on serum levels of sulfones, sulfonamides and isonia zid. Some investigators8 1° 27 believe that the acetyla ting phenotype is intimately related to the serum levels of these drugs, whereas others24 disagree.
In view of the above considerations, the objecti ves of the present study were to determine the isoniazid acetylating phenotype and to evaluate correlation of it with G6PD and glutathione reductase activity and with serum levels of free and total sulfadoxin in patients with paracoccidioidomycosis.
MATERIAL AND METHODS
The present study was conducted at the Paracocciodioidomycosis Outpatient Clinic of the Division of Infectious and Parasitologic Diseases of the School of Medicine of Botucatu/UNESP, São Paulo, Brazil, from 1987 to 1989. Thirty-nine patients (6 females and 33 males, aged 19 to 64 years) with a confirmed diagnosis of paracoccidioidomycosis were studied. The clinical form of the diseasel3 was chronic in 29 and subacute progressive in 10 patients. All patients Tropical 24:111-114, ahrjun, 1991 were under maintenance treatment with one tablet (500 mg) of sulfadoxin twice a week. As recommended by Mendes1®, the medication was taken on Mondays and Thursdays and blood samples were collected on Wednesdays at about 2:00 p.m.. All patients had been under maintenance treatment for at least one month and followed medical prescriptions rigorously. They were tested for isoniazid acetylating phenotype and G6PD and glutathione reductase activities and sub mitted to measurement of hematocrit, hemoglobin and serum levels of free and total sulfadoxin.
Isoniazid acetylating phenotype was determi ned before the beginning of treatment by the colorime tric test of Eidus et aU2 and Hodgkin et al1^ and the patients were classified as fast acetylators when acetylated isoniazid was more than 65% and as slow acetylators when acetylated isoniazid was less than 65%, according these authors *2 15 G6PD and glutathione reductase activities were determined by the technique standardized by Barra viera et aP. The normal values were 221.10±21.06 ^.g/min for G6PD activity, and 81.27±9.54 fxg/min for glutathione reductase. Hematocrit ievels were determined by the microhematocrit method and hemo globin levels by the cyanomethemoglobin method20.
Serum sulfadoxin levels were measured by the techique of Bratton & Marshall11 which is used to evaluate free and total sulfadoxin levels.
Two study groups were proposed for evaluation of the results: Group 1: slow acetylators; and Group 2: fast acetylators.
Data were analyzed statistically using the pai red "t" test2^. To determine the interrelationship of the variables, the linear correlation coefficient betwe en pairs of variables was calculated. Table 1 showed that 21(53.84%) patients were slow acetylator and 18(46.16%) fast acetylators.
RESULTS

Analysis of the results presented in
Hematocrit and hemoglobin levels were redu ced only among male patients, 5 of whom (27.77%) were fast acetylators and 6(28.57%) slow acetylators.
G6PD activity was decreased in 5(23.80%) slow acetylators and 4(22.22%) fast acetylators. Glutathione reductase activity was decreased in 14(66.66%) slow acetylators and in 12(66.66%) fast acetylators.
Serum levels of free and total sulfadoxin were significatively higher among slow acetylators (p < 0,05 and p < 0,02, respectively). There was a negative correlation between slow acetylating plenotype and serum level of free sulfa (ro,ol = -0,45).
DISCUSSION
Isoniazid acetylating phenotype and G6PD and glutathione reductase activities are genetically deter mined traits^ 6 8 10 12 15 The first is determined by major autosomal genes and is related to the acetylating capacity of hepatic acetyl transferase. One of the functions of this enzyme is to inactivate sulfones, sulfonamides and isoniazid10 1215. Population stu dies'9 26 have demonstrated two types of acetylators, i.e., fast and slow, the frequency of each varying from population to population. American Indians, Japanese and Eskimos most often present a fast acetylating phenotype2^. In Brazil, Beiguelman et al10 evaluated the acetylating phenotype of Caucasian and Black patients with tuberculosis and detected 57% slow acetylators among Caucasians and 50% among Blacks. In the present study, the prevalence of acetyla ting phenotype was quite similar to that found by these investigators1®. G6PD activity is determined by genes located on the X chromosome14 21. Thus, only females can manifest homozygous or heterozygous trait. In the present study, 3 patients heterozygous for G6PD deficiency were detected. Among the six G6PD-deficient male patients, only two developed anemia. It should be pointed out that reduced number of patients On the other hand, individuals chronically using sulfamide derivatives are known to suffer stimulation o f glutathione synthetase which causes increased synthesis of reduced glutathione23. These individuals eventually show an increase in glutathione reductase activity. The present findings showed exactly the contrary, i.e., a decrease in glutathione reductase activity, strengthening the hypothesis that the nutri tional deficiency of riboflavin may be the limiting factor in glutathione reductase activity. It should be pointed out that all anemic patients presented decrea sed glutathione reductase activity. It has been reported1 6 9 14 21 that the same drugs that cause anemia among G6PD-deficient individuals can cause anemia among glutathione reductase-deficient subjects. In this case, the nutritional deficiency on the one hand, the chronic effect of sulfadoxin on the other, may have strongly contributed to the onset of anemia.
The relationship between acetylating phenotype and serum levels o f fast-excretion sulfamide deriva tives are controversial24 27. Vree et al27 and Barraviera et al8, when evaluating the serum sulfadiazine levels of patients using these drugs and their relationship with the acetylating phenotype, found more elevated drug levels and decreased renal function among slow acetylators. The present results agree with those reported in these studies8 27 and clearly demonstrate the difference in serum sulfa doxin levels between slow and fast acetylators. On the other hand, serum levels of free sulfadoxin were always above 50 jag/ml in all patients studied, levels considered therapeutic by Padilha-Gonçalves22. Thus, the posology used was appropriat since it maintained satisfactory serum levels of the drug even among fast acetylators.
Finally, determination of acetylator phenotype and of serum sulfadoxin level as well as their rela tionships with G6PD and glutathione reductase acti vities represents an important and very useful para meter since it permits better clinical follow-up of the patients, with early observation of the possible onset of anemia and of therapeutic faults due to insufficient circulating levels of the drug. Tropical 24: 111-115, ahr-jun, 1991 3. Barraviera 
